With $165M In Financing From Novo, Repair Impact Fund To Support Early-Stage Development Of Innovative Antibiotics

Financial Times: Novo to invest $165m in first ‘superbug’ venture fund
“The first venture fund dedicated to investing in companies fighting superbugs resistant to modern drugs is to be launched on Wednesday, with $165m finance from Novo Holdings of Denmark. The Repair Impact Fund aims to put $20m-$40m a year over three to five years into European and U.S. start-ups and early-stage ventures developing innovative antibiotics aimed at bacteria the World Health Organization regards as the greatest threat to human health…” (Cookson, 2/27).